Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 25;8(1):273-284.
doi: 10.14338/IJPT-D-20-00076. eCollection 2021 Summer.

The Role of Particle Therapy in Adenoid Cystic Carcinoma and Mucosal Melanoma of the Head and Neck

Daniel K Ebner  1 , Timothy D Malouff  2 , Steven J Frank  3 , Masashi Koto  1
Affiliations

The Role of Particle Therapy in Adenoid Cystic Carcinoma and Mucosal Melanoma of the Head and Neck

Daniel K Ebner et al. Int J Part Ther. .

Abstract

Particle irradiation is suitable for resistant histologies owing to a combination of improved dose delivery with potential radiobiologic advantages in high linear energy transfer radiation. Within the head and neck, adenoid cystic carcinoma and mucosal melanoma are two such histologies, being radioresistant and lying closely proximal to critical structures. Here, we review the use of particle irradiation for adenoid cystic carcinoma and mucosal melanoma of the head and neck.

Keywords: adenoid cystic carcinoma; carbon-ion radiotherapy; mucosal melanoma; particle radiotherapy; proton radiotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Steven J. Frank, MD, is an associate editor of the International Journal of Particle Therapy. Dr Frank is a paid consultant/advisory board member for Varian and advisory board member for Hitachi and Breakthrough Chronic Care. He is founder and director of and has received grants and personal fees from C4 Imaging. He reports grants from Eli Lilly, Elekta, grants and honoraria from Hitachi and personal fees from Boston Scientific and the National Comprehensive Cancer Center. The authors have no other relevant conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
PubMed and ClinicalTrials.gov database search strategy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Guazzo E, Panizza B. Management of advanced adenoid cystic carcinoma infiltrating the skull base: a contemporary review. J Neurooncol. 2020;150:419–27. - PubMed
    1. Tinganelli W, Durante M, Hirayama R, Kramer M, Maier A, Kraft-Weyrather W, Furusawa Y, Friedrich T, Scifoni E. Kill-painting of hypoxic tumours in charged particle therapy. Sci Rep. 2015;5:17016. - PMC - PubMed
    1. Paganetti H, Niemierko A, Ancukiewicz M, Gerweck LE, Goitein M, Loeffler JS, Suit HD. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys. 2002;53:407–21. - PubMed
    1. Wang L, Wang X, Li Y, Han S, Zhu J, Wang X, Molkentine DP, Blanchard P, Yang Y, Zhang R, Sahoo N, Gillin M, Zhu XR, Zhang X, Myers JN, Frank SJ. Human papillomavirus status and the relative biological effectiveness of proton radiotherapy in head and neck cancer cells. Head Neck. 2017;39:708–15. - PubMed
    1. Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. J Clin Oncol. 2020;38:1569–79. - PMC - PubMed

LinkOut - more resources